Dr Reddy's Laboratories | Zee News

Advertisement

NewsDr Reddy's Laboratories

Dr Reddy's Laboratories News

15 Sep 2021

Single-dose COVID vaccine Sputnik Light for phase 3 trials in India

In April, Sputnik V had received an emergency use authorisation in India The committee had noted that Sputnik Light was the same as component-1 of Sputnik V It added that its safety and immunogenicity data in the Indian population was already generated in a trial

13 Jul 2021

Sputnik V soft launch not put on hold, clarifies Dr Reddy's Laboratories

Dr Reddy's Laboratories said that the soft launch of Sputnik V has not been put on hold. The Hyderabad-based company said that it will strengthen the commercial roll-out of the Russian vaccine in the coming weeks.

28 Jun 2021

Dr Reddy's Laboratories announces commercial launch of anti-COVID 2-DG drug

Dr Reddy's Laboratories on June 28 announced the commercial launch of the anti-COVID 2-DG drug. The Hyderabad based pharmaceutical company said that it will supply the drug to major Govt and pvt hospitals. The 2-DG manufactured by Dr Reddy's has a purity of 99.5%.

2DG COVID medicine

20 May 2021

Beware! 2DG COVID medicine will not see the daylight before June

The generic drugmaker released a statement on social media saying the anti-COVID remedy oral drug 2DG has not yet been launched into the market. Here, we advise our readers to remain vigilant and refrain themselves from falling into the trap of black marketers who lure them by offering the 2DG drug in exchange for a hefty amount. We request you to share this article with your friends and relative so as to alert your surroundings.

coronavirus vaccine

17 Oct 2020

Good news! Phase 2 trial of this COVID-19 vaccine may resume in India soon

Dr Reddy's Laboratories has collaborated with The Russian Direct Investment Fund (RDIF) to conduct clinical trials of the Sputnik V vaccine as well as its distribution. Sputnik V is also the first vaccine candidate in the world to attain regulatory approval. Sputnik V, which was developed by Gamaleya Institute in Moscow, was licensed for use in Russia in August.

Dr Reddy's Laboratories

08 Sep 2017

Dr Reddy's shares slip nearly 3%; mcap drops by Rs 1,082 crore

In terms of equity volume, 1.57 lakh shares of the company were traded on BSE and over 17 lakh shares changed hands on NSE during the day.

Dr Reddy's Laboratories

01 Sep 2017

Dr Reddy's gets favourable verdict in patent litigation in US

Dr Reddy's stock was the biggest gainer among 30 Sensex scrips.

Dr Reddy's Laboratories

28 Aug 2017

Class action lawsuit filed against Dr Reddy's in US

Drug firm Dr Reddy's Laboratories on Monday said a class action lawsuit has been filed against it in the US by an investor alleging misleading statements in violation of the US federal securities laws.

Dr Reddy's Laboratories

17 Feb 2017

DRL says no claims against it for monetary damages in US patent case

There are no claims against drug major Dr Reddy's Laboratories informed the company for monetary damages informed the company through a BSE filing on Friday.

27 Oct 2016

7 FDI proposals worth Rs 100 crore get FIPB approval

Inter-ministerial body FIPB on Thursday cleared seven proposals envisaging foreign investment of Rs 100 crore.

Dr Reddy's Laboratories

06 Apr 2016

USFDA actions hurting exports, need govt intervention: Dr Reddy's

Asserting that regulatory action by the US Food and Drug Administration (USFDA) on leading Indian firms has impacted exports from the country, Dr Reddy's Laboratories Chairman Satish Reddy Wednesday asked for a dialogue between government and US health regulator.

Dr Reddy's Laboratories

07 Mar 2016

Dr Reddy's to invest in startups

Dr Reddy's Laboratories (DRL) will be investing in startups besides partnering with external entities for research and innovation.

Dr Reddy's Laboratories

17 Feb 2016

Dr Reddy's board approves share buyback for Rs 1,569.4 crore

Drug major Dr Reddy's will buyback around 44.85 lakh shares, accounting for about 2.6 percent of the existing paid up capital of the company, for up to Rs 1,569.4 crore.

Dr Reddy's Laboratories

09 Feb 2016

Dr Reddy's Q3 net profit rises marginally to Rs 579 crore

Dr Reddy's Laboratories today posted a marginal increase in consolidated net profit at Rs 579.2 crore for the third quarter ended December 31, hit by weak sales in the emerging markets like Russia, CIS nations and Romania.

20 Dec 2015

Tata Motors only Indian firm on top-50 global R&D list

Tata Motors has entered the top-50 league of the world's biggest companies in terms of their R&D investments, topped by German automaker Volskwagen.

Dr Reddy's Laboratories

26 Nov 2015

USFDA gives Dr Reddy's addl time to respond to warning letter

Dr Reddy's Laboratories Ltd (DRL) Thursday said the USFDA has extended the time-frame for replying to the warning letter issued to the company by about two weeks to December 7.

Dr Reddy's Laboratories

26 Nov 2015

Dr Reddy's shares slump 8.5%; m-cap dips Rs 4,746 crore

The stock fell on reports that the US Food and Drug Administration (USFDA) might withhold approval of the company's fresh drugs and stop import after it found several violations at three of its plants.

Dr Reddy's Laboratories

25 Nov 2015

US FDA warns of DRL drug import ban if flaws are not fixed

The US Food and Drug Administration (US FDA), which had issued a warning letter to Dr Reddy's Laboratories over quality issues, has said it might withhold approval of the company's fresh drugs and stop import if no corrective action is taken.

Dr Reddy's Laboratories

19 Nov 2015

Dr Reddy's accused of making false claims about financials, shares slump 7%

US-based law firm Lundin Law, which specialises in securities litigations is investigating claims against Dr Reddy's Laboratories for possible violations of federal security laws, which the drug maker has denied.

10 Nov 2015

US court asks Dr Reddy's Laboratories to halt generic sale of esomeprazole

A US court has directed Dr Reddy's Laboratories to temporarily stop selling its generic version of esomeprazole in the US market.

Loading...

NEWS ON ONE CLICK